BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 20700766)

  • 21. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
    Kroiss A; Putzer D; Frech A; Decristoforo C; Uprimny C; Gasser RW; Shulkin BL; Url C; Widmann G; Prommegger R; Sprinzl GM; Fraedrich G; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1800-8. PubMed ID: 24072345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer.
    Ocak M; Demirci E; Kabasakal L; Aygun A; Tutar RO; Araman A; Kanmaz B
    Nucl Med Commun; 2013 Nov; 34(11):1084-9. PubMed ID: 23939265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
    Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
    Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 131I-MIBG, 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT scans in a patient with extra adrenal paraganglioma associated with SDH-B gene mutation.
    Kasaliwal R; Malhotra G; Lila A; Bandgar T; Shah NS
    Clin Nucl Med; 2015 May; 40(5):439-41. PubMed ID: 25742231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of
    Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T
    J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
    King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma.
    Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C
    J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.
    Janssen I; Blanchet EM; Adams K; Chen CC; Millo CM; Herscovitch P; Taieb D; Kebebew E; Lehnert H; Fojo AT; Pacak K
    Clin Cancer Res; 2015 Sep; 21(17):3888-95. PubMed ID: 25873086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
    Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
    Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
    Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative analysis of
    Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
    Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.
    Kong G; Schenberg T; Yates CJ; Trainer A; Sachithanandan N; Iravani A; Ravi Kumar A; Hofman MS; Akhurst T; Michael M; Hicks RJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5091-5099. PubMed ID: 30977831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.
    Janssen I; Chen CC; Taieb D; Patronas NJ; Millo CM; Adams KT; Nambuba J; Herscovitch P; Sadowski SM; Fojo AT; Buchmann I; Kebebew E; Pacak K
    J Nucl Med; 2016 Feb; 57(2):186-91. PubMed ID: 26564322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.